# Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

> **NCT03173066** · PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 1 (actual)

## Conditions studied

- Pulmonary Embolism

## Interventions

- **DRUG:** Ferumoxytol

## Key facts

- **NCT ID:** NCT03173066
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173066, "Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03173066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*